Johnson & Johnson is accelerating work on its experimental Ebola vaccine and said on Wednesday that it aims to have 1 million doses ready in 2015, of which 250,000 are expected to be available by May. There is currently no proven vaccine against the deadly disease but several companies are racing to develop products and clinical tests on two - from GlaxoSmithKline and NewLink Genetics - are already under way. The World Health Organization hopes that tens of thousands of people in West Africa, including frontline healthcare workers at high risk of infection, can start receiving Ebola vaccines from January as part of large-scale clinical trials.